LMT Avocats Life Sciences Team – 2022 Highlights

Photo: – From left to right: Antoine Lemétais, Ghislaine Issenhuth, Cristian Rawlins, Olivier Samyn

2022 was marked by the development and strengthening of the transaction practices of our Paris member firm, Lmt Avocats’ Life Sciences team. Read their summary of the year here:

Now co-managed by 3 partners and supported by 6 associates, our team has strong expertise and a solid reputation in mergers and acquisitions, pharmaceutical products acquisitions and fundraising transactions. The Life Sciences team also handles leading cases in product liability, unfair competition, contractual litigation and regulatory matters. Thanks to its multidisciplinary and commitment, our Life Sciences team offers a full range of services, for which we are regularly quoted in specialist journals.

In particular, Lmt Avocats is continuously recognised as an “unbeatable”/”excellent” law firm in regulatory and transactional matters by the French magazine “Décideurs”, which recently awarded it a “Gold Special Distinction in Health Pharma – RegulatoryLaw” at the “Sommets du Droit” held on 25 January 2023.

As a member of the PLG and INBLF networks, our firm continues to deploy its services internationally in order to meet the needs of its French and foreign clients in cross-border transactions.
We are particularly proud to have successfully advised our clients on their projects in this industry. We congratulate them on their success and wish them all the best for 2023.

▪ Advising a French pharmaceutical company in its acquisition from large foreign pharmaceutical groups of various pharmaceutical products including a neuroleptic drug and an antithrombotic drug, each marketed mainly in Europe.
▪ Advising a European pharmaceutical company in the acquisition of a local anaesthetic drug marketed in the United States from an American pharmaceutical company.
▪ Advising a French pharmaceutical company in the acquisition of pharmaceutical products, including a hypolipidemic drug and an antiserotoninergic drug marketed in several countries in Asia, Europe, Africa and the Middle East, from a major Swiss company.
▪ Advising a French pharmaceutical company in its acquisition from large French pharmaceutical group of both a vaccine against Japanese encephalitis marketed in Asia and a related industrial manufacturing site
▪ Advising two pharmaceutical companies in the acquisition through a corporate joint venture of an anti-parasite drug marketed mainly in Africa.
▪ Advising a French pharmaceutical company and its management in a secondary LBO alongside a leading British investment fund.
▪ Advising a biotech company specialising in drug regeneration in several fund-raising transactions.
▪ Advising the founders of a start-up specialising in the in vitro diagnosis of infectious diseases, as part of a seed fundraising transaction.
▪ Acting as litigation lawyers for a French pharmaceutical company in:
– a “pourvoi en cassation” (review of procedure rules and compliance with the law) against the interim order suspending the marketing authorisation for its product,
– summary review proceedings against the same order,
and representing the client in the proceedings on the merits against the product’s marketing authorisation as well as an action for unfair competition based on the use of data from its marketing authorisation file.
▪ Representing an Irish pharmaceutical company in proceedings before the French “Conseil d’Etat” against a decision refusing to register the product on the list of reimbursable products and obtaining its annulment, thus setting a precedent for the conditions under which a refusal to register can be decided by the Ministry.
▪ Representing and advising an international pharmaceutical company in the context of:
– proceedings initiated against it by a company under Lithuanian law relating to an alleged abrupt termination of business relationships and
– a counterclaim for the return of its marketing authorisations, used in Lithuania.
This complex litigation, with multiple procedures both in France and in Lithuania, enabled our client to recover the use of its MAs.
▪ Representing a major player in the pharmaceutics publishing industry in proceedings brought by an association against the Covid-19 vaccine campaign on the basis of an alleged blatantly unlawful conduct by the ANSM, and obtaining an order against the claimant to pay a civil fine.
▪ Representing and advising laboratories holding marketing authorisations for generic drugs in the context of serial litigation in matters of product liability, both before the judicial courts and before the CCIs (Conciliation & Compensation Commissions for nosocomial infections and iatrogenic diseases – Commissions de Conciliation et d’Indemnisation des Accidents Médicaux des Affections Iatrogènes et des Infections Nosocomiales).